Inhibikase Therapeutics (IKT) Institutional Ownership → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free IKT Stock Alerts $1.76 -0.23 (-11.56%) (As of 05/16/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$248.12KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$1.93M Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023 Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023 Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817% 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/6/2022 Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022 Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022 Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022 Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021 Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021 BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021 Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021 Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021 Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021 Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021 Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021 FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021 Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021 Millennium Management LLC11,224$67K0.0%N/A0.112% 5/18/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/17/2021 HRT Financial LP11,614$69K0.0%N/A0.115% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, the following institutional investors and hedge funds held shares of Inhibikase Therapeutics shares: Armistice Capital LLC ($259K), Blair William & Co. IL ($114K), Hamilton Lane Advisors LLC ($50K), and Koshinski Asset Management Inc. ($49K), Barclays PLC ($41K).Learn more on IKT's institutional investors. What percentage of Inhibikase Therapeutics stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics stock? The following institutional investors have purchased Inhibikase Therapeutics stock in the last 24 months: Hamilton Lane Advisors LLC ($82.82K), Koshinski Asset Management Inc. ($65.38K), Blair William & Co. IL ($50K), and Barclays PLC ($11.46K). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 209,649 shares in the last 24 months. This purchase volume represents approximately $1.02M in transactions. Which Inhibikase Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), and Hamilton Lane Advisors LLC ($69.02K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 379,516 shares in the last 24 months. This volume of shares sold represents approximately $1.93M in transactions. Related Companies: CELZ Major Shareholders BCDA Major Shareholders GENE Major Shareholders FNCH Major Shareholders COEP Major Shareholders ELOX Major Shareholders WINT Major Shareholders TVGN Major Shareholders PMCB Major Shareholders SNTI Major Shareholders This page (NYSE:IKT) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.